Download Free Anticancer Treatments And Cardiotoxicity Book in PDF and EPUB Free Download. You can read online Anticancer Treatments And Cardiotoxicity and write the review.

Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions presents cutting edge research on the adverse cardiac effects of both radiotherapy and chemotherapy, brought together by leaders in the field. Cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in cancer survivors and is one of the most common post-treatment issues among survivors of adult cancer. Early detection of the patients prone to developing cardiotoxicity, taking in to account the type of treatment, history and other risk factors, is essential in the fight to decrease cardiotoxic mortality. This illustrated reference describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment. In addition, new guidelines on imaging for the screening and monitoring of these patients are also presented. Anticancer Treatments and Cardiotoxicity is an essential reference for those involved in the research and treatment of cardiovascular toxicity. - Provides algorithms essential for the use of imaging, and biomarkers for the screening and monitoring of patients - Written by world-leading experts in the field of cardiotoxicity - Includes high-quality images, case studies, and test questions - Describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment
Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions presents cutting edge research on the adverse cardiac effects of both radiotherapy and chemotherapy, brought together by leaders in the field. Cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in cancer survivors and is one of the most common post-treatment issues among survivors of adult cancer. Early detection of the patients prone to developing cardiotoxicity, taking in to account the type of treatment, history and other risk factors, is essential in the fight to decrease cardiotoxic mortality. This illustrated reference describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment. In addition, new guidelines on imaging for the screening and monitoring of these patients are also presented. Anticancer Treatments and Cardiotoxicity is an essential reference for those involved in the research and treatment of cardiovascular toxicity.
Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more. Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications—arrhythmias, heart failure, and even death. - Adopts a translational approach and comprehensively covers the basic science, mechanisms and concepts of cardio-oncology - Outlines the current knowledge of biomarkers in cancer therapy-related cardiotoxicity - Provides an understanding of the mechanisms of cardiovascular toxicity of various therapies that may lead to the identification of novel targets to reduce vascular complications
This comprehensive guide describes the aftercare that is appropriate in young cancer patients and discusses in detail the risk and detection of treatment sequelae. It explains the impacts on body and mind of both the disease itself and the different risk-adapted cancer treatments currently in use. Clear guidance is provided on diagnosis and management of the principal treatment-related toxicities in different organs and organ systems and for a wide variety of tumor types. In addition, the role of genetic polymorphisms in the development of adverse therapy-related outcomes is explored, and advice offered on genetic counselling. As the number of long-term survivors of childhood cancer and of cancer in young adults continues to grow, so issues surrounding potential sequelae, second malignancies, and quality of life are becoming ever more important. All practitioners involved in the care of young cancer patients will find this book to be a helpful source of up-to-date information and assistance.
The Department of Cardiology at The University of Texas MD Anderson Cancer Center was established on September, 1, 2000. In the past 15 years, we have evaluated and treated more than 10,000 cancer patients with cancer ther¬apy-related cardiovascular complications. Three years ago, we initiated the MD Anderson Practice (MAP) project to distillate our practice patterns into al¬gorithms to be shared with the onco-cardiology community. Because cancer is often an exclusion criterion for cardiology studies, purely evidence-based man¬agement of cancer therapy-related cardiovascular complications is not possible. With this vacuum of knowledge, various "guidelines" have proliferated that are either misleading or difficult to practice. In this manual, we present 16 MAPs that have been extensively reviewed by the cardiologists at MD Anderson. These MAPs should be considered our best practices rather than "guidelines." These MAPs will be updated frequently to reflect advances in the field. This manual con¬sists of MAPs, figures, and tables. We hope you will find these materials useful to your practice and provide us with feedback to improve these MAPs.
This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.
The possibility of getting a cardiovascular disease or cancer increases with advancing age. At the same time, relevant improvements in cancer therapy have resulted in the improvement of quality of life and the increasement of the survival rate of such patients. As a result we have larger number of patients that experience the cardiac side effects of chemotherapy. The extent of cardiotoxicity is variable, depending on the type of drug used, combination with other drugs, prior mediastinal radiotherapy and the presence of cardiovascular risk factors or history of heart disease. Early detection of the patients proneness for developing cardiotoxicity is the key issue to decrease morbidity and mortality. It also facilitates more tailored therapeutic interventions. Therefore, the collaboration and interaction of cardiology and oncology may contribute to reducing the cardiovascular adverse effects and improving the results in the treatment of patients with cancer.